Personalizing medicine in geriatric oncology

Journal of Clinical Oncology

Volumn 32, Issue 24, 2014, Pages 2581-2586

  Walko, Christine M ^a   McLeod, Howard L ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CAPECITABINE; CODEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DOCETAXEL; DRUG METABOLIZING ENZYME; ENDOXIFEN; FLECAINIDE; FLUOROURACIL; FLUOXETINE; METHOTREXATE; OPIATE; PACLITAXEL; PAROXETINE; TAMOXIFEN; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER HORMONE THERAPY; CANCER THERAPY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG MONITORING; FIRST PASS EFFECT; GERIATRIC CARE; GERMLINE MUTATION; GLOMERULUS FILTRATION; HUMAN; KIDNEY TUBULE ABSORPTION; NEOPLASM; NEUROPATHY; NEUTROPENIA; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; URINARY EXCRETION; AGE; AGED; FEMALE; GERIATRICS; MALE; METABOLISM; NEOPLASMS; ONCOLOGY; PATHOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; FEMALE; GERIATRICS; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MEDICAL ONCOLOGY; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84906270694     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.9047     Document Type: Review

References (66)

1. Walko CM, McLeod H: Pharmacogenomic progress in individualized dosing of key drugs for cancer patients. Nat Clin Pract Oncol 6:153-162, 2009
2. Gurney H: Dose calculations of anticancer drugs: A review of the current practice and introduction of an alternative. J Clin Oncol 14:2590-2611, 1996 (Pubitemid 26300128)
3. American Cancer Society: Cancer Facts and Figures 2013. Atlanta, GA, American Cancer Society, 2013
4. Lewis JH, Kilgore ML, Goldman DP, et al: Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21:1383-1389, 2003 (Pubitemid 46606420)
5. Talarico L, Chen G, Pazdur R: Enrollment of elderly patients in clinical trials for cancer registration: A 7-year experience by the US Food and Drug Administration. J Clin Oncol 22:4626-4631, 2004 (Pubitemid 41185131)
6. Wilkinson GR: The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans. Adv Drug Deliv Rev 27:129-159, 1997 (Pubitemid 27417870)
7. Bosilkovska M, Walder B, Besson M: Analgesics in patients with hepatic impairment: Pharmacology and clinical implications. Drugs 72:1645-1649, 2012
8. Schmucker DL: Liver function and phase I drug metabolism in the elderly: A paradox. Drugs Aging 18:837-851, 2001 (Pubitemid 34073129)
9. Vestal RE, Cusack BJ, Crowley JJ, et al: Aging and the response to inhibition and induction of theophylline metabolism. Exp Gerontol 28:421-433, 1993 (Pubitemid 23226559)
10. Bachmann KA, Belloto RJ Jr: Differential kinetics of phenytoin in elderly patients. Drugs Aging 15:235-250, 1999 (Pubitemid 29438142)
11. Schwartz JB: The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther 82:87-96, 2007 (Pubitemid 46944201)
12. Klotz U: Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 41:67-76, 2009
13. Van Pottelbergh G, Vaes B, Adriaensen W, et al: The glomerular filtration rate estimated by new and old equations as a predictor of important outcomes in elderly patients. BMC Med 12:27, 2014
14. Willems JM, Vlasveld T, den Elzen WP, et al: Performance of Cockcroft-Gault, MDRD, and CKDEPI in estimating prevalence of renal function and predicting survival in the oldest old. BMC Geriatr 13:113, 2013
15. Stevens LA, Coresh J, Schmid CH, et al: Estimating GFR using serum cystatin C alone and in combination with serum creatinine: A pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 51:395-406, 2008 (Pubitemid 351273480)
16. Burstein HJ, Prestrud AA, Seidenfeld J, et al: American Society of Clinical Oncology clinical practice guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784-3796, 2010
17. Crivellari D, Sun Z, Coates AS, et al: Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: The BIG 1-98 trial. J Clin Oncol 26:1972-1979, 2008
18. Mürdter TE, Schroth W, Bacchus-Gerybadze L, et al: Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 89:708-717, 2001
19. Wu X, Hawse JR, Subramaniam M, et al: The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res 69:1722-1727, 2009
20. Desta Z, Ward BA, Soukhova NV, et al: Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310:1062-1075, 2004 (Pubitemid 39108928)
21. Bradford LD: CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3:229-243, 2002 (Pubitemid 34223859)
22. Sideras K, Ingle JN, Ames MM, et al: Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol 28:2768-2776, 2010
23. Borges S, Desta Z, Li L, et al: Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implications for optimization of breast cancer treatment. Clin Pharmacol Ther 80:61-74, 2006 (Pubitemid 43946844)
24. Jin Y, Desta Z, Sterns V, et al: CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30-39, 2005
25. Ohyama K, Nakajima M, Suzuki M, et al: Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: Prediction of in vivo drug interactions. Br J Clin Pharmacol 49:244-253, 2000 (Pubitemid 30150986)
26. Hoskins JM, Carey LA, McLeod HL: CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 9:576-586, 2009
27. Schroth W, Goetz MP, Hamann U, et al: Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302:1429-1436, 2009
28. Province MA, Goetz MP, Brauch H, et al: CYP2D6 genotype and adjuvant tamoxifen: Metaanalysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-227, 2014
29. Lien EA, Søiland H, Lundgren S, et al: Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment. Breast Cancer Res Treat 141:243-248, 2013
30. Kisanga ER, Mellgren G, Lien EA: Excretion of hydroxylated metabolites of tamoxifen in human bile and urine. Anticancer Res 25:4487-4492, 2005 (Pubitemid 41729501)
31. Doki K, Homma M, Kuga K, et al: Effects of CYP2D6 genotypes on age-related change of flecainide metabolism: Involvement of CYP1A2-mediated metabolism. Br J Clin Pharmacol 68:89-96, 2009
32. Rahman A, Korzekwa KR, Grogan J, et al: Selective biotransformation of taxol to 6 alphahydroxytaxol by human cytochrome P450 2C8. Cancer Res 54:5543-5546, 1994
33. Smorenburg CH, ten Tije AJ, Verweij J, et al: Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer. Eur J Cancer 39:196-202, 2003 (Pubitemid 36057070)
34. Lichtman SM, Hollis D, Miller AA, et al: Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J Clin Oncol 24:1846-1851, 2006 (Pubitemid 46638982)
35. Mielke S, Sparreboom A, Steinberg SM, et al: Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 11:4843-4850, 2005 (Pubitemid 41557204)
36. Gelderblom H, Mross K, ten Tije AJ, et al: Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. J Clin Oncol 20:574-581, 2002 (Pubitemid 34072542)
37. Sakakibara T, Inoue A, Sugawara S, et al: Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer. Ann Oncol 21:795-799, 2010
38. Lee JJ, Swain SM: Peripheral neuropathy induced by microtubule- stabilizing agents. J Clin Oncol 24:1633-1642, 2006 (Pubitemid 46638788)
39. Gogas H, Shapiro F, Aghajanian C, et al: The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer. Gynecol Oncol 61:22-26, 1996 (Pubitemid 26108524)
40. Hertz DL, Roy S, Motsinger-Reif AA, et al: CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol 24:1472-1478, 2013
41. Leskelä S, Jara C, Leandro-García LJ, et al: Polymorphisms in cytochromes P450 2C8 and 3A4 are associated with paclitaxel neurotoxicity. Pharmacogenomics J 11:121-129, 2011
42. Dai D, Zeldin DC, Blaisdell JA, et al: Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11:597-607, 2001 (Pubitemid 32953585)
43. Marsh S, Somlo G, Li X, et al: Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J 7:362-365, 2007 (Pubitemid 47484774)
44. Naraharisetti SB, Lin YS, Rieder MJ, et al: Human liver expression of CYP2C8: Gender, age, and genotype effects. Drug Metab Dispos 38:889-893, 2010
45. Sissung TM, Mross K, Steinberg SM, et al: Association of ABCB1 genotypes with paclitaxelmediated peripheral neuropathy and neutropenia. Eur J Cancer 42:2893-2896, 2006 (Pubitemid 44755257)
46. Marsh S, Paul J, King CR, et al: Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: The Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 25:4528-4535, 2007 (Pubitemid 350035308)
47. Deandrea S, Montanari M, Moja L, et al: Prevalence of undertreatment in cancer pain: A review of published literature. Ann Oncol 19:1985-1991, 2008
48. Barbera L, Seow H, Husain A, et al: Opioid prescription after pain assessment: A populationbased cohort of elderly patients with cancer. J Clin Oncol 30:1095-1099, 2012
49. Baillie SP, Bateman DN, Coates PE, et al: Age and pharmacokinetics of morphine. Age Ageing 18:258-262, 1989
50. Dean M: Opioids in renal failure and dialysis patients. J Pain Symptom Manage 28:497-504, 2004 (Pubitemid 39422488)
51. Crews KR, Gaedigk A, Dunnenberger HM, et al: Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther 91:321-326, 2012
52. Mignat C, Wille U, and Ziegler A: Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes. Life Sci 56:793-799, 1995
53. Osborne R, Thompson P, Joel S, et al: The analgesic activity of morphine-6-glucuronide. Br J Clin Pharmacol 34:130-138, 1992
54. Kirchheiner J, Schmidt H, Tzvetkov M, et al: Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 7:257-265, 2007 (Pubitemid 47202488)
55. Ciszkowski C, Madadi P, Phillips MS, et al: Codeine ultrarapid-metabolism genotype, and postoperative death. N Engl J Med 361:827-828, 2009
56. Gasche Y, Daali Y, Fathi M, et al: Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 351:2827-2831, 2004 (Pubitemid 40051906)
57. Sanoff HK, Bleiberg H, Goldberg RM: Managing older patients with colorectal cancer. J Clin Oncol 25:1891-1897, 2007 (Pubitemid 46854423)
58. Walko CM, Lindley C: Capecitabine: A review. Clin Ther 27:23-44, 2005 (Pubitemid 40347299)
59. Sobrero A, Guglielmi A, Grossi F, et al: Mechanism of action of fluoropyrimidines: Relevance to the new developments in colorectal cancer chemotherapy. Semin Oncol 27:72-77, 2000
60. Rich TA, Shepard RC, Mosley ST: Four decades of continuing innovation with fluorouracil: Current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 22:2214-2232, 2004 (Pubitemid 41095158)
61. Van Kuilenburg AB, Meinsma R, Zoetekouw L, et al: Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: High prevalence of the IVS14+1g>a mutation. Int J Cancer 101:253-258, 2002 (Pubitemid 34970893)
62. Yen JL, McLeod HL: Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer 43:1011-1016, 2007 (Pubitemid 46483039)
63. Milano G, Etienne MC, Cassuto-Viguier E, et al: Influence of sex and age on fluorouracil clearance. J Clin Oncol 10:1171-1175, 1992
64. Gamelin E, Boisdron-Celle M, Delva R, et al: Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: Results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol 16:1470-1478, 1998 (Pubitemid 28175768)
65. Saif MW, Choma A, Salamone SJ, et al: Pharmacokinetically guided dose adjustment of 5-fluorouracil: A rational approach to improving therapeutic outcomes. J Natl Cancer Inst 101:1543-1552, 2009
66. Gamelin E, Delva R, Jacob J, et al: Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: Results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 26: 2099-2105, 2008